Clinical Trial Bill to be Tabled (India)
This article was originally published in PharmAsia News
Executive Summary
The proposed Central Drug Authority (CDA) bill that includes imprisonment of five years and a fine of Rs 20 lakh for those found violating norms of clinical trials will be tabled during the upcoming monsoon session of the Parliament. Drugs controller general of India Dr M. Venkateswarulu says the CDA bill has been framed with an aim to check the increasing clinical trials being conducted in the country. "As of today, there's no act or law to monitor the clinical research and drug trials in the country," he states. "There cannot be any compromise in clinical research and the trials that are being done in the country," he adds. "There is need for more transparency and knowing about the associated risk factors." He further says the draft CDA bill is ready, and the Parliament will take a decision on the final quantum of punishment. Expressing concern over the growing tendency of pharma industry to outsource work, he asserts there should be a limit to outsourcing of work. "The people who undergo clinical trials of drugs should not be exploited. They should be well informed about the risks. Their safety should be ensured. There should be proper communication with people while conducting trials." Thomas Adam, president and chief executive officer of the Association of Clinical Research Professionals (ACRP), says clinical trials will begin to 'migrate' to India in large numbers. "Young talent will be the driving force in attracting this to India," he says. (Click here for more
You may also be interested in...
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.